Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
The EULER 2022 Congress took place this year from June 1st-4th, 2022. During that time, rheumatology professionals met to discuss trends, guidelines, and patient care within the field of rheumatology.…
Adolescence is the phase which exists between childhood and adulthood; therefore, people who are between ages 10-19 are typically considered to be adolescents. How does adolescence change the way people…
Cannabidiol (CBD) has been explored as a potential therapy for a variety of different conditions, ranging from various forms of epilepsy to dystonia to Parkinson's disease. Now, researchers are questioning…
According to a recent article, children with juvenile idiopathic arthritis experienced higher rates of joint inflammation during the COVID-19 lockdown. Juvenile Idiopathic Arthritis (JIA) Juvenile idiopathic arthritis (JIA) proves that…
In a study published in the research journal Scientific Reports, CD71+ erythroid cells (CECs) have an immunoregulatory function. They often appear in people with cardiopulmonary or hemolytic disorders, as well as in…
July is recognized as Juvenile Idiopathic Arthritis Awareness Month. Though arthritis is often considered an illness that is associated with old age, it is estimated that around 300,000 children in…
As reported in Physicians Weekly; a new study wanted to further characterize Enthesitis-related arthritis (ERA), a subtype of juvenile idiopathic arthritis (JIA) that is often is accompanied by anterior uveitis,…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Innovent Biologics has recently received approval from the National Medical Products Administration (NMPA) for their juvenile idiopathic arthritis (JIA) treatment, SULINNO. It has been approved to treat JIA, rheumatoid arthritis,…
According to new research, children with juvenile idiopathic arthritis (JIA) are more likely to experience uveitis flares as their arthritis progresses. Medscape notes that researchers wanted to understand how and…
According to a story from gopresstimes.com, Lily Laurent, a 13 year old student at De Pere middle school in Wisconsin, has lived with juvenile idiopathic arthritis for nine years. While…
July is recognized as Juvenile Idiopathic Arthritis Awareness Month. Though arthritis is often considered an illness that is associated with old age, it is estimated that around 300,000 children in…
According to Juvenile Arthritis News, treating juvenile idiopathic arthritis early helps reduce symptoms, nearly "inactivating" the condition. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) JIA Registry found that early…
According to a recent article in BioMed Central, an international task force formed in 2018 created guidelines for the treatment of juvenile idiopathic arthritis (JIA). Treatment targets were identified…
.jpg)
Janssen R&D, a division of Johnson & Johnson (J&J), has partnered with the UK Biobank and others according to a recent news release by 3BL Media. It is noteworthy…
Being a teenager is difficult. There are plenty of difficulties and awkward things that teens deal with every day. For those who have a rheumatic disease, their lives can…
It wasn’t until the 1980s that the medical field really started talking about the need to emotionally support patients, especially those with chronic illnesses. This is partly due to the…
According to a story from Juvenile Arthritis News, the results of a recent phase 3 clinical trial indicate that the drug tofacitinib (marketed as Xeljanz) can be an effective treatment…
According to a story from Juvenile Arthritis News, a recent study from China has found that early treatment with infliximab (marketed as Remicade) can reduce inflammation and indicators of active…
According to a story from Juvenile Arthritis News, a recent study has found that the drug leflunomide (marketed as Arava) may be a viable treatment for juvenile idiopathic arthritis patients,…
Juvenile idiopathic arthritis (JIA) is a rare condition affecting children. Like all patients, these children are told what treatment they need and then they are expected to comply. However, researchers in…
The Study Juvenile idiopathic arthritis (JIA) is a rare disease that causes inflammation in the joints. It is of unknown origin and has no cure. Previous investigations in studies with…
Sun's out, school's closed, summer's in full swing -- let's set aside some time to talk about juvenile idiopathic arthritis in the month of July! What is JIA? Juvenile idiopathic…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
